{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/parkinsons-disease/how-up-to-date-is-this-topic/changes/","result":{"pageContext":{"chapter":{"id":"29a7b8ce-d32b-5e9d-a682-56084e34b727","slug":"changes","fullItemName":"Changes","depth":2,"htmlHeader":"<!-- begin field 77cbdad1-e124-4601-9f02-b537520bea26 --><h2>Changes</h2><!-- end field 77cbdad1-e124-4601-9f02-b537520bea26 -->","summary":null,"htmlStringContent":"<!-- begin item aaef8025-4041-4008-9d69-8067e0127d13 --><!-- begin field e1f8731d-a570-4928-b256-bb8f65d8dbde --><p><strong>February 2018 </strong>— minor update. Updated QS164 Parkinsons Disease added to new evidence section.</p><p><strong>January 2018</strong> — reviewed. A literature search was conducted in January 2018 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials published since the last revision of this topic. The topic has been updated in line with the National Institute for Health and Care Excellence (NICE) clinical guideline <em>Parkinson's disease in adults: diagnosis and management </em>(2017). The sections on prevalence and impulse control disorders have been expanded, and the sections on the management of motor and non-motor complications and specialist treatments of Parkinson's disease have been updated.</p><!-- end field e1f8731d-a570-4928-b256-bb8f65d8dbde --><!-- end item aaef8025-4041-4008-9d69-8067e0127d13 -->","topic":{"id":"6cfe5031-c78a-5fcf-8597-8688ef0d3a41","topicId":"ac61656d-8e8b-48b8-bf1d-49f506afadb6","topicName":"Parkinson's disease","slug":"parkinsons-disease","lastRevised":"Last revised in February 2018","chapters":[{"id":"8bebf6b8-3a72-530a-ac48-52a8618f2267","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"044ab1d2-584c-5ed9-ab24-f7c8d64ef959","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"51b4e173-4f8a-5f7a-9e4a-fff68f32b031","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"29a7b8ce-d32b-5e9d-a682-56084e34b727","slug":"changes","fullItemName":"Changes"},{"id":"e1bb005f-8b49-5ae3-9670-a888d5def19a","slug":"update","fullItemName":"Update"}]},{"id":"fbbb2e6c-5309-5aa6-a27f-d6f508b6f994","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"40c62f24-40c5-5619-88aa-963a7de0d17d","slug":"goals","fullItemName":"Goals"},{"id":"2b0ddbc1-3535-545a-8be3-996ce778ee4d","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"a8f322a5-4ac1-50c9-8391-83584bd86b30","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"d2a1f92e-43cd-575e-bcbd-7bd0e6792634","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"e860c3e6-3288-5ee1-bd77-a6d4aa0c3006","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"d3463e24-bbaa-5d3a-aca9-0d6da87a47f3","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"644e166b-8434-55a7-859c-6479b609051a","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"935e4ed2-12f3-5857-9a26-8a3beaed429c","slug":"definition","fullItemName":"Definition"},{"id":"58a49a4b-fb27-55f3-9afb-3c816842a76a","slug":"prevalence","fullItemName":"Prevalence"},{"id":"ce592a68-6b1f-5015-8125-2facfdcc4afe","slug":"prognosis","fullItemName":"Prognosis"},{"id":"8a05334f-9e7a-5662-b166-d86bd3c7546e","slug":"complications","fullItemName":"Complications"}]},{"id":"3951c9c0-49fe-5d17-8d1d-4c42b0b95c3f","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"e7662ffa-e42d-5bb5-9025-2ba5f6587a6f","slug":"when-to-suspect","fullItemName":"When to suspect"},{"id":"435dc95c-73c1-5636-953b-feb3d7f82aaf","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"196d12bb-51bd-5a0b-872d-c7b60bde431b","fullItemName":"Management","slug":"management","subChapters":[{"id":"38b7e750-e77e-5791-a127-6e5192b69597","slug":"suspected-parkinsons-disease","fullItemName":"Scenario: Suspected Parkinson's disease"},{"id":"fae10e1b-26bc-523c-bc3b-ec45e56860ca","slug":"confirmed-parkinsons-disease","fullItemName":"Scenario: Confirmed Parkinson's disease"},{"id":"c0adefb6-a71d-5b3c-bc2d-b86a13219e16","slug":"end-stage-parkinsons-disease","fullItemName":"Scenario: End-stage Parkinson's disease"}]},{"id":"d811822d-b022-5b69-8514-00e15d349643","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"83038956-9818-52c8-9415-85ab073e43aa","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"757d939c-8a84-5a32-847b-38d850b38230","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"17a6cb12-1c93-5aff-bc74-2c2cee2f97ee","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"bd851d10-0cce-5204-8b2e-54ae60c5767f","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"9d232b23-7764-59d5-8026-50fff91a905b","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"7deed303-b70d-5459-8ca1-d40e9dbf3c88","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"1a717fd3-80b2-587f-8d46-3f904380d76a","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"51b4e173-4f8a-5f7a-9e4a-fff68f32b031","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?"},"subChapters":[{"id":"2e9a9155-44bc-5447-a8f9-3d5ffa342f46","slug":"previous-changes","fullItemName":"Previous changes","depth":3,"htmlHeader":"<!-- begin field cb62ee99-69ed-4193-9aab-39aa8c23c40e --><h3>Previous changes</h3><!-- end field cb62ee99-69ed-4193-9aab-39aa8c23c40e -->","summary":null,"htmlStringContent":"<!-- begin item fcec4460-3da0-442a-8f5c-cecd4fc89270 --><!-- begin field 95a5c1b7-df40-418d-9a01-a8ceb1b59c6d --><p><strong>December 2016</strong> — minor updates. Safinamide (Xadago<sup>®</sup>) has been added as a possible adjuvant therapy in the section on specialist management of motor symptoms, in line with the manufacturer's Summary of Product Characteristics (SPC, 2016). Information that taking domperidone with high doses of apomorphine increases the risk of QT prolongation, and that people should only take them concomitantly after assessment of cardiac risk factors and ECG monitoring, has been added to this topic, in line with the Medicines and Healthcare products Regulatory Agency (MHRA) recommendations (2016).</p><p><strong>October to December 2015</strong> — reviewed. A literature search was conducted in October 2015 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials published since the last revision of this topic. The topic has undergone restructuring, but no major changes to the recommendations have been made.</p><p><strong>December 2014 </strong>— minor update. Change to the text with regards to sildenafil to improve clarity.</p><p><strong>November 2014 </strong>— minor update. Removal of Selected List Scheme (SLS) status for generic sildenafil products.</p><p><strong>July 2013 </strong>— minor update. Links to the DVLA website have been updated. </p><p><strong>November 2012 </strong>— minor update. The links to the electronic medicines website (www.medicines.org.uk) have been updated. </p><p><strong>March 2012 </strong>— minor update. The 2012/2013 QOF indicators have been added to this topic. Issued in April 2012. </p><p><strong>January 2012 </strong>— minor update. McNeil Products Ltd, in collaboration with the Medicines and Healthcare products Regulatory Agency (MHRA), has published new safety data regarding the association of domperidone with an increased risk of serious ventricular arrhythmias or sudden cardiac death. This topic has been updated to reflect their advice on dosing, adverse effects, and drug interactions. Issued in February 2012. </p><p><strong>January 2012 </strong>— minor update to clarify that rotigotine is a transdermal preparation and not an oral preparation. Issued in February 2012.</p><p><strong>March 2011 </strong>— topic structure revised to ensure consistency across CKS topics — no changes to clinical recommendations have been made. </p><p><strong>August 2010 </strong>— minor update. The European Medicines Agency (EMEA) has recently advised that modafinil should be used only for the treatment of narcolepsy. The EMEA considers that the risks (cardiovascular, neuropsychiatric, skin reactions) outweigh the benefits for other indications, such as daytime hypersomnolence. Issued in August 2010. </p><p><strong>December 2009 </strong>— minor update. Advice about venlafaxine and duloxetine in people taking selegiline or rasagiline has been added to the section on Drugs to avoid in the section on Confirmed Parkinson's disease. Issued in December 2009. </p><p><strong>January to June 2009 </strong>— converted from CKS guidance to CKS topic structure. The evidence-base has been reviewed in detail, and recommendations are more clearly justified and transparently linked to the supporting evidence. There have been no major changes to the recommendations.</p><p><strong>December 2008</strong> — minor update. Drug safety advice regarding cabergoline and bromocriptine added from the Medicines and Healthcare products Regulatory Agency (MHRA) Drug Safety Update, specifically regarding the risk of cardiac fibrosis with long-term use of ergot-derived dopamine agonists. Issued in January 2009. </p><p><strong>September 2008</strong> — minor correction to the Changes section. Issued September 2008. </p><p><strong>July to September 2006</strong> — rewritten. Validated in December 2006 and issued in January 2007. </p><p><strong>October 2005</strong> — minor technical update. Issued in November 2005. </p><p><strong>November 2004</strong> — reviewed. Validated in March 2005 and issued in April 2005. </p><p><strong>September 2001</strong> — rewritten. Validated in November 2001 and issued in April 2002. </p><p><strong>May 1999</strong> — reviewed.</p><p><strong>April 1998</strong> — written.</p><!-- end field 95a5c1b7-df40-418d-9a01-a8ceb1b59c6d --><!-- end item fcec4460-3da0-442a-8f5c-cecd4fc89270 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}